COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics
GET POWR RATINGS... FREE!
CMPS Stock Price Chart Interactive Chart >
CMPS Price/Volume Stats
| Current price | $10.38 | 52-week high | $21.50 |
| Prev. close | $10.58 | 52-week low | $6.54 |
| Day low | $10.28 | Volume | 190,200 |
| Day high | $10.53 | Avg. volume | 267,408 |
| 50-day MA | $9.35 | Dividend yield | N/A |
| 200-day MA | $11.37 | Market Cap | 442.52M |
COMPASS Pathways PLC ADR (CMPS) Company Bio
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Latest CMPS News From Around the Web
Below are the latest news stories about COMPASS PATHWAYS PLC that investors may wish to consider to help them evaluate CMPS as an investment opportunity.
10 Best Psychedelic Stocks to Buy According to Hedge FundsIn this article, we discuss 10 best psychedelic stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy According to Hedge Funds. Data Bridge Market Research predicts that the psychedelic drugs market will expand at a compound annual growth rate […] |
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull MarketEnterprising investors who pay attention to this can set themselves up for future success by buying into great growth stocks while in the hard landing phase of the volatility. Two biopharma stocks are particularly appealing right now as buy candidates before the next bull market has a chance to buoy their shares once again. It develops liquid biopsies for cancer screening, treatment selection, treatment efficacy evaluation, and recurrence detection, which means that patients don't need to experience the invasiveness of a traditional biopsy to get the health information their doctors need to determine a course of treatment. |
2 Growth Stocks With Incredible Potential in the Next 5 YearsSpecifically, there are no guarantees that positive early results will lead to positive later-stage clinical trials results, despite yearslong efforts put in to develop these drugs and therapies. More often than not, pharma and biotech investors can only gauge the chances of a company's success by weighing the results of its clinical trials against its available cash runway. |
COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor ConferenceLONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows: Cowen 43rd Annual Health Care Conference: ‘Neuropsych Panel’ at 12:50pm ET on March 6, 2023 and host investor meetingsOppenheimer 33rd Annual Healthcare Conference: presentation at 10:00am ET on March 13, 2023 and hos |
COMPASS Pathways plc (NASDAQ:CMPS) Q4 2022 Earnings Call TranscriptCOMPASS Pathways plc (NASDAQ:CMPS) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today’s conference, […] |
CMPS Price Returns
| 1-mo | 27.68% |
| 3-mo | 29.27% |
| 6-mo | -3.26% |
| 1-year | -19.47% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 29.27% |
| 2022 | -63.67% |
| 2021 | -53.61% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...